Traders bought shares of UnitedHealth Group (NYSE:UNH) on weakness during trading hours on Friday following insider selling activity. $180.76 million flowed into the stock on the tick-up and $112.26 million flowed out of the stock on the tick-down, for a money net flow of $68.50 million into the stock. Of all stocks tracked, UnitedHealth Group had the 15th highest net in-flow for the day. UnitedHealth Group traded down ($0.70) for the day and closed at $235.06Specifically, Director Kenneth Irwin Shine sold 202 shares of the stock in a transaction on Thursday, April 19th. The stock was sold at an average price of $237.42, for a total transaction of $47,958.84. Following the completion of the transaction, the director now directly owns 28,948 shares of the company’s stock, valued at $6,872,834.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William C. Ballard, Jr. sold 10,000 shares of the stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $246.38, for a total value of $2,463,800.00. Following the transaction, the director now directly owns 76,637 shares of the company’s stock, valued at $18,881,824.06. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 77,019 shares of company stock valued at $17,879,133. 0.89% of the stock is currently owned by corporate insiders.
Several brokerages have weighed in on UNH. Zacks Investment Research lowered UnitedHealth Group from a “buy” rating to a “hold” rating in a report on Wednesday, March 28th. Credit Suisse Group reissued a “buy” rating on shares of UnitedHealth Group in a report on Friday, March 9th. JPMorgan Chase increased their price objective on UnitedHealth Group to $266.00 and gave the company an “overweight” rating in a report on Wednesday. Oppenheimer increased their price objective on UnitedHealth Group from $260.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, January 17th. Finally, Citigroup increased their price objective on UnitedHealth Group from $235.00 to $268.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $251.13.
The company has a debt-to-equity ratio of 0.56, a current ratio of 0.71 and a quick ratio of 0.73. The stock has a market capitalization of $228,136.20, a PE ratio of 23.34, a price-to-earnings-growth ratio of 1.36 and a beta of 0.77.
UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings data on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.91 by $0.13. UnitedHealth Group had a return on equity of 22.06% and a net margin of 5.41%. The company had revenue of $55.19 billion for the quarter, compared to the consensus estimate of $54.90 billion. During the same quarter last year, the business posted $2.37 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. analysts expect that UnitedHealth Group will post 12.61 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Aevitas Wealth Management Inc. purchased a new stake in shares of UnitedHealth Group in the fourth quarter worth $102,000. Exane Derivatives raised its position in UnitedHealth Group by 15,333.3% during the fourth quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock valued at $102,000 after purchasing an additional 460 shares in the last quarter. Pathstone Family Office LLC purchased a new stake in UnitedHealth Group during the fourth quarter valued at about $129,000. Trustcore Financial Services LLC purchased a new stake in UnitedHealth Group during the fourth quarter valued at about $133,000. Finally, Baystate Wealth Management LLC raised its position in UnitedHealth Group by 64.9% during the fourth quarter. Baystate Wealth Management LLC now owns 762 shares of the healthcare conglomerate’s stock valued at $186,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 86.78% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Traders Buy UnitedHealth Group (UNH) on Weakness After Insider Selling” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/22/traders-buy-unitedhealth-group-unh-on-weakness-after-insider-selling.html.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.